IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial - Top_Thought_Leaders - MDSpire

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

At ARVO 2026, Arshad M. Khanani, MD, MA, FASRS, presented phase 2 data on vamikibart, an IL-6 inhibitor, in diabetic macular edema.

  • By

  • Arshad M. Khanani, MD, MA, FASRS

  • Arshad M. Khanani, MD, MA, FASRS

  • May 1, 2026

  • 4 min

Share

Top Thought Leaders in Ophthalmology

Brief introduction explaining scope and methodology.

Original Source(s)

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

  • by Arshad M. Khanani, MD, MA, FASRS, Arshad M. Khanani, MD, MA, FASRS

  • May 1, 2026

Related Content

Ocular Surface Optimization: The Best First Step in Modern Cataract Surgery

Why a healthy preoperative ocular surface is no longer optional

The New Era of Postoperative Inflammation Management

What surgeons need to know about managing post-cataract inflammation

Success and Failure Rates with Increased-Range-of-Focus IOLs 

IRoF lenses offer high success, with some outperforming others